Less Than 1 Year
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One
Business Acquisition [Axis]
Business Acquisition [Axis]
Olumiant®
Olumiant [Member]
Olumiant [Member]
Net amount reclassified from accumulated other comprehensive loss
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)
Total reclassifications, net of tax
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Number of pending lawsuits
Loss Contingency, Pending Claims, Number
Schedule of asset acquisitions
Schedule of Research and Development Assets Acquired Other than Through Business Combination [Table Text Block]
Deferred tax assets
Deferred Income Tax Assets, Net
Lebrikizumab
Lebrikizumab [Member]
Lebrikizumab [Member]
Entity Address, Postal Zip Code
Entity Address, Postal Zip Code
Neuroscience
Neuroscience [Member]
Revenue to unaffiliated customers, Neuroscience
Net investment (gains) losses
Gain (Loss) on Investments
Other diabetes
Other Diabetes [Member]
Other Diabetes [Member]
Business Combinations
Business Combinations Policy [Policy Text Block]
Debt Instrument [Axis]
Debt Instrument [Axis]
Effect from interest rate contracts
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments
Line of credit facility, maximum borrowing capacity
Line of Credit Facility, Maximum Borrowing Capacity
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Abstract]
Revenue, information used to determine revenue recognized, change in accounting estimate, percent (less than)
Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent
Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent
Retirement of treasury shares (in shares)
Treasury Stock, Shares, Retired
Damages awarded, value
Loss Contingency, Damages Awarded, Value
Foreign currency exchange contracts
Foreign Exchange Contract [Member]
6-10 Years
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10
Schedule of other–net, (income) expense
Schedule of Other Nonoperating Income (Expense) [Table Text Block]
Financial Instruments [Domain]
Financial Instruments [Domain]
Fair Value Measurement [Domain]
Fair Value Measurement [Domain]
Number of plaintiffs
Loss Contingency, Number of Plaintiffs
Cash flow hedges:
Cash Flow Hedge [Abstract]
Cash Flow Hedge [Abstract]
Other investing activities, net
Payments for (Proceeds from) Other Investing Activities
Statistical Measurement [Domain]
Statistical Measurement [Domain]
Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc. [Member]
Rigel Pharmaceuticals, Inc.
Marketable equity securities
Marketable Securities [Member]
Marketable Securities [Member]
Stated interest rate
Debt Instrument, Interest Rate, Stated Percentage
Asset Acquisition [Table]
Asset Acquisition [Table]
Additional paid-in capital
Additional Paid in Capital, Common Stock
Reclassification out of Accumulated Other Comprehensive Income [Axis]
Reclassification out of Accumulated Other Comprehensive Income [Axis]
Net periodic benefit cost
Defined Benefit Plan, Net Periodic Benefit Cost (Credit)
Purchase of treasury shares
Treasury Stock, Value, Acquired, Cost Method
Net income
Net income
Net income
Net Income (Loss) Attributable to Parent
1-5 Years
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five
Document Information [Line Items]
Document Information [Line Items]
Subsequent Event Type [Axis]
Subsequent Event Type [Axis]
Amortization of prior service cost
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)
Equity Component [Domain]
Equity Component [Domain]
Subsequent Event Type [Domain]
Subsequent Event Type [Domain]
Scenario [Axis]
Scenario [Axis]
Cost of common stock in treasury
Treasury Stock, Common, Value
Asset impairment and other special charges
Asset Impairment Charges (Recoveries) And Other Special Charges
Asset Impairment Charges (Recoveries) And Other Special Charges
Total
Debt Securities, Available-for-Sale
Business acquisition, share price (in dollars per share)
Business Acquisition, Share Price
Hedging Designation [Domain]
Hedging Designation [Domain]
Derivative Instrument [Axis]
Derivative Instrument [Axis]
Employee Litigation
Employee Litigation [Member]
Employee Litigation [Member]
Total other liabilities
Liabilities, Noncurrent
Statement of Cash Flows [Abstract]
Statement of Cash Flows [Abstract]
Entity Address, State or Province
Entity Address, State or Province
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Inputs, Level 1 [Member]
Alternative investments, unfunded commitments, payment period
Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period
Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period
Defined Benefit Pension and Retiree Health Benefit Plans
Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member]
Net Cash Provided by Operating Activities
Net Cash Provided by (Used in) Operating Activities
Summary the contractual maturities of our investments in debt securities measured at fair value
Debt Securities, Available-for-Sale [Table Text Block]
Innovent Biologics, Inc.
Innovent Biologics, Inc. [Member]
Innovent Biologics, Inc.
Other neuroscience
Other Neuroscience [Member]
Other Neuroscience [Member]
Costs, expenses, and other:
Costs and Expenses [Abstract]
Retirement benefit plans
Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component
Pretax net losses on cash flow hedges expected to be reclassified during the next 12 months
Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net
Change in Accounting Estimate by Type [Axis]
Change in Accounting Estimate by Type [Axis]
Trulicity®
Trulicity [Member]
Trulicity [Member]
Legal Entity [Axis]
Legal Entity [Axis]
Long-term debt
Long-Term Debt, Excluding Current Maturities
Change in Accounting Estimate, Type [Domain]
Change in Accounting Estimate, Type [Domain]
Byetta
Byetta [Member]
Byetta
Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax
Geographical [Axis]
Geographical [Axis]
Cash Flows from Investing Activities
Net Cash Provided by (Used in) Investing Activities [Abstract]
Other foreign countries
Other Foreign Countries [Member]
Other Foreign Countries [Member]
Accrued retirement benefits (Note 8)
Liability, Defined Benefit Plan, Noncurrent
Cash
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents
Potential achievements
Collaborative Arrangement, Rights and Obligations, Rights (Obligations)
Terms or rights and obligations under collaborative arrangements.
Schedule of reclassifications out of accumulated other comprehensive loss
Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]
Other current liabilities
Derivative Liability, Current
Entity Common Stock, Shares Outstanding
Entity Common Stock, Shares Outstanding
Fair Value Hierarchy and NAV [Domain]
Fair Value Hierarchy and NAV [Domain]
Schedule of significant milestones and revenue recognized
Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]
Basaglar®
Basaglar
Basaglar [Member]
Basaglar [Member]
Short-term investments
Debt Securities, Available-for-Sale, Current
Document Type
Document Type
Schedule of Change in Accounting Estimate [Table]
Schedule of Change in Accounting Estimate [Table]
Contingent value right, monthly reduction (in cents per share)
Business Acquisition, Contingent Value Right, Regulatory Approval Delay, Monthly Reduction
Business Acquisition, Contingent Value Right, Covenant, Regulatory Approval Occurs
Severance
Severance Costs
Other assets and liabilities, net
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net
Asset Acquisition [Axis]
Asset Acquisition [Axis]
Product and Service [Domain]
Product and Service [Domain]
Effective portion of cash flow hedges
Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]
Entity Shell Company
Entity Shell Company
Other, net of tax
Accumulated Gain (Loss), Net, Cash Flow Hedge And Foreign Currency Adjustment, Including Portion Attributable To Noncontrolling Interest [Member]
Accumulated Gain (Loss), Net, Cash Flow Hedge And Foreign Currency Adjustment, Including Portion Attributable To Noncontrolling Interest
Financial Instrument [Axis]
Financial Instrument [Axis]
Effective portion of risk-management instruments that was recognized in other comprehensive income (loss), cash flow hedges
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax
Number of patents
Loss Contingency, Number Of Patents
Loss Contingency, Number Of Patents
Subsequent Event
Subsequent Event [Member]
Schedule of amounts recorded for contract liabilities
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]
Document Period End Date
Document Period End Date
Asset Impairment, Restructuring, and Other Special Charges
Restructuring, Impairment, and Other Activities Disclosure [Text Block]
Precision Biosciences, Inc.
Precision Biosciences, Inc. [Member]
Precision Biosciences, Inc.
Schedule of components of other comprehensive income (loss)
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]
Total assets
Assets
Asset impairment, restructuring, and other special charges (Note 5)
Total asset impairment, restructuring, and other special charges
Restructuring, Settlement and Impairment Provisions
Earnings per share:
Earnings Per Share [Abstract]
Equity securities
Equity Securities, FV-NI, Current
Forward-starting interest rate swaps
Interest Rate Swap [Member]
Taltz®
Taltz [Member]
Taltz [Member]
Net Cash Used for Financing Activities
Net Cash Provided by (Used in) Financing Activities
Investments (Note 6)
Noncurrent investments
Long-Term Investments
Stock repurchase program, authorized amount
Stock Repurchase Program, Authorized Amount
Employee compensation
Employee-related Liabilities, Current
Asset-backed securities
Asset-Backed Securities [Member]
Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments
Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments
3.95% Notes Due 2049
3.95% Notes Due 2049 [Member]
3.95% Notes Due 2049 [Member]
Verzenio®
Verzenio [Member]
Verzenio [Member]
Foreign Currency Translation Gains (Losses)
Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]
Interest cost
Defined Benefit Plan, Interest Cost
4.15% Notes Due 2059
4.15% Notes Due 2059 [Member]
4.15% Notes Due 2059 [Member]
Other comprehensive income (loss), net of tax
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest
Effective portion of risk-management instruments that was recognized in other comprehensive income (loss), net investment hedges
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax
Debt extinguishment loss (Note 6)
Loss on extinguishment of debt
Gain (Loss) on Extinguishment of Debt
Income Tax Contingency [Table]
Income Tax Contingency [Table]
Schedule of effects of risk-management instruments were recognized in other–net, (income) expense
Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]
Other comprehensive income (loss) before reclassifications
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax
Payments to acquire businesses
Payments to Acquire Businesses, Gross
Schedule of fair value, by balance sheet grouping
Fair Value, by Balance Sheet Grouping [Table Text Block]
Derivative Contract [Domain]
Derivative Contract [Domain]
Net Investment Hedges
Net Investment Hedging [Member]
Entity Registrant Name
Entity Registrant Name
China
CHINA
Equity method investments
Equity Method And Other Investments [Member]
Equity Method and Other Investments [Member]
Entity Address, City or Town
Entity Address, City or Town
Retirement Benefits
Retirement Benefits [Text Block]
Total equity
Beginning balance
Ending balance
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest
Minimum
Minimum [Member]
Other oncology
Other Oncology [Member]
Other Oncology [Member]
Noncontrolling interests
Stockholders' Equity Attributable to Noncontrolling Interest
Statement of Financial Position [Abstract]
Statement of Financial Position [Abstract]
Entity Emerging Growth Company
Entity Emerging Growth Company
Collaboration and other revenue associated with prior period transfers of intellectual property
Royalty [Member]
Inventory write-down
Inventory Write-down
Acquired IPR&D
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Abstract]
Brazil
BRAZIL
Common Stock in Treasury
Treasury Stock, Common [Member]
Defined Benefit Pension Plans
Pension Plan [Member]
Financial Instruments
Fair Value Disclosures [Text Block]
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Trading Symbol
Trading Symbol
Entity File Number
Entity File Number
Foreign currency-denominated notes
Hedged Fixed Rate Debt [Member]
Hedged Fixed-Rate Debt [Member]
Beginning balance (in shares)
Ending balance (in shares)
Treasury Stock, Common, Shares
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Acquired in-process research and development
Acquired In-process Research And Development
The amount of EXPENSE related to research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore written off in the period of acquisition (INCOME STATEMENT)
Research and development
Research and Development Expense
Purchases of short-term investments
Payments to Acquire Short-Term Investments
Description of Derivative Risk Management
Derivatives, Policy [Policy Text Block]
Effective income tax rate, percentage
Effective Income Tax Rate Reconciliation, Percent
Cash equivalents
Cash and Cash Equivalents, Fair Value Disclosure
Derivative liability, notional amount
Derivative Liability, Notional Amount
Acquisitions
Business Combination Disclosure [Text Block]
Acquisition date fair value of consideration transferred
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net
Fair value hedges:
Fair Value Hedge [Abstract]
Fair Value Hedge [Abstract]
Revenue (Note 2)
Revenue
Revenues
Income Taxes
Income Tax Disclosure [Text Block]
Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative
Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative [Member]
Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member]
Payment for debt extinguishment
Payment for Debt Extinguishment or Debt Prepayment Cost
Alimta®
Alimta [Member]
Alimta [Member]
Basic (in dollars per share)
Earnings Per Share, Basic
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan Disclosure [Line Items]
Swap Swiss Francs to U.S. Dollars
Swap Swiss Francs To U.S. Dollars [Member]
Swap Swiss Francs To U.S. Dollars [Member]
Total Eli Lilly and Company shareholders' equity
Stockholders' Equity Attributable to Parent
Cash and cash equivalents at January 1
Cash and Cash Equivalents at September 30
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations
Prepaid expenses and other
Prepaid Expense, Current
Erbitux®
Erbitux [Member]
Erbitux [Member]
Entity Interactive Data Current
Entity Interactive Data Current
7 1/8% Notes due 2025
7 1/8% Notes Due June 1, 2025 [Member]
7 1/8% Notes Due June 1, 2025 [Member]
Amount of receivable derecognized
Transfer of Financial Assets Accounted for as Sales, Amount Derecognized
0.500% Notes due 2033
.500% Notes Due 2033 [Member]
.500% Notes Due 2033 [Member]
Portion at Fair Value Measurement
Portion at Fair Value Measurement [Member]
Dividends paid
Payments of Dividends
Retained Earnings
Retained Earnings [Member]
Proceeds from sales and maturities of short-term investments
Proceeds from Sale of Short-Term Investments
Common Stock
Common Stock [Member]
Stock-based compensation
Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture
Purchases of common stock
Payments for Repurchase of Common Stock
Contingent consideration liability, other noncurrent liabilities
Business Combination, Contingent Consideration, Liability
Short-term commercial paper borrowings
Commercial Paper
Costs, expenses, and other
Cost Of Sales, Operating Expenses, And Other-net
Cost Of Sales, Operating Expenses, And Other-net
Class of Stock [Axis]
Class of Stock [Axis]
Buy US Dollar Sell Chinese Yuan
Buy US Dollar Sell Chinese Yuan [Member]
Buy US Dollar Sell Chinese Yuan
Immunology
Immunology [Member]
Immunology [Member]
Statement [Table]
Statement [Table]
Product Liability
Product Liability [Member]
Product Liability
Document Quarterly Report
Document Quarterly Report
Current Assets
Assets, Current [Abstract]
Statistical Measurement [Axis]
Statistical Measurement [Axis]
Proceeds from sales of noncurrent investments
Proceeds from Sale of Long-Term Investments
Asset Acquisition [Domain]
Asset Acquisition [Domain]
Purchase of treasury shares (in shares)
Treasury Stock, Shares, Acquired
Reclassification out of Accumulated Other Comprehensive Income [Domain]
Reclassification out of Accumulated Other Comprehensive Income [Domain]
Retained earnings
Retained Earnings (Accumulated Deficit)
Sales returns, rebates, and discounts
Sales Returns and Allowances [Member]
Accumulated Other Comprehensive Loss
AOCI Including Portion Attributable to Noncontrolling Interest [Member]
Other non-cash operating activities, net
Other Operating Activities, Cash Flow Statement
Accounts receivable, net of allowances of $17.7 (2022) and $22.5 (2021)
Accounts Receivable, after Allowance for Credit Loss, Current
Equity Components [Axis]
Equity Components [Axis]
Scenario [Domain]
Scenario [Domain]
Litigation Case Type [Domain]
Litigation Case [Domain]
Document Fiscal Year Focus
Document Fiscal Year Focus
Cash Flows from Operating Activities
Net Cash Provided by (Used in) Operating Activities [Abstract]
Statement [Line Items]
Statement [Line Items]
Number of claims dismissed
Litigation, Claims Dismissed, Number
Litigation, Claims Dismissed, Number
Realized gross gains on sales
Available for Sale Securities and Equity Securities, FV-NI, Realized Gain
Available for Sale Securities and Equity Securities, FV-NI, Realized Gain
Other–net, (income) expense (Note 11)
Other–net, (income) expense
Nonoperating Income (Expense)
Fair Value Hierarchy and NAV [Axis]
Fair Value Hierarchy and NAV [Axis]
Marketing, selling, and administrative
Selling, General and Administrative Expense
Loss Contingencies [Table]
Loss Contingencies [Table]
Unrealized gross losses
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Net product revenue
Product [Member]
Accumulated Other Comprehensive Loss
AOCI Attributable to Parent [Member]
Other Comprehensive Income (Loss)
Comprehensive Income (Loss) Note [Text Block]
Other
Other Product, Total [Member]
Other Product, Total [Member]
Net purchases of property and equipment
Payments to Acquire Productive Assets
Document Transition Report
Document Transition Report
Local Phone Number
Local Phone Number
Implementation of New Financial Accounting Standard
New Accounting Pronouncements, Policy [Policy Text Block]
Equity investments without readily determinable fair values
Equity Securities without Readily Determinable Fair Value, Amount
Document Information [Table]
Document Information [Table]
Goodwill
Goodwill
Proceeds from sales
Proceeds from Sale of Equity and Available for Sale Securities
Proceeds from Sale of Equity and Available for Sale Securities
Unrealized Net Gains (Losses) on Securities
Unrealized net gains/losses on securities
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Including Noncontrolling Interest [Member]
Collaborative arrangement, rights and obligations, percentage (up to)
Collaborative Arrangement, Rights and Obligations Percent
Description of rights and obligations under the collaborative arrangements, including but not limited to - percent share in various revenues and costs, percent interest earned on related party notes.
Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Income taxes (Note 7)
Tax benefit
Income Tax Expense (Benefit)
Geographical [Domain]
Geographical [Domain]
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Deferred tax liabilities
Deferred Income Tax Liabilities, Net
Net change in short-term borrowings
Proceeds from Short-Term Debt
Income Statement [Abstract]
Income Statement [Abstract]
Hedging Relationship [Axis]
Hedging Relationship [Axis]
Additional Paid-in Capital
Additional Paid-in Capital [Member]
Document Fiscal Period Focus
Document Fiscal Period Focus
Humalog, Humulin and Forteo
Humalog, Humulin, And Forteo [Member]
Humalog, Humulin, And Forteo
Cost of sales
Cost of Goods and Services Sold
Purchases of in-process research and development
Purchased In-process Research And Development
The amount of CASH paid for research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore, written off in the period of acquisition (CASH FLOWS).
Cyramza®
Cyramza [Member]
Cyramza [Member]
Diluted (in shares)
Weighted Average Number of Shares Outstanding, Diluted
2.125% Notes due 2030
2.125% Notes Due June 3, 2030 [Member]
2.125% Notes Due June 3, 2030 [Member]
Milestone Payments, Sales-based
Milestone Payments, Sales-based [Member]
Milestone Payments, Sales-based [Member]
Property and equipment, accumulated depreciation
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Loss Contingency, Nature [Domain]
Loss Contingency, Nature [Domain]
Diabetes
Diabetes [Member]
Diabetes [Member]
Loss Contingencies [Line Items]
Loss Contingencies [Line Items]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain]
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Other
Other Product [Member]
Other Product [Member]
Recognized actuarial loss
Defined Benefit Plan, Actuarial Gain (Loss), Immediate Recognition as Component in Net Periodic Benefit (Cost) Credit
Buy British Pounds and Sell U.S. Dollars
Buy British Pound and Sell US Dollars [Member]
Buy British Pound and Sell US Dollars [Member]
Realized gross losses on sales
Available for sale Securities and Equity Securities, FV-NI, Realized Loss
Available for sale Securities and Equity Securities, FV-NI, Realized Loss
Common stock
Common Stock, Value, Issued
Carrying Amount
Reported Value Measurement [Member]
Debt Instrument, Name [Domain]
Debt Instrument, Name [Domain]
Derivatives used in net investment hedge, net of tax
Derivatives used in Net Investment Hedge, Net of Tax
Business Acquisition, Acquiree [Domain]
Business Acquisition, Acquiree [Domain]
Contingencies
Commitments and Contingencies, Policy [Policy Text Block]
Schedule of effective portion of risk-management instruments that was recognized in other comprehensive income (loss), cash flow hedges
Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]
Actuarial losses, net
Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Including Portion Attributable to Noncontrolling Interest [Member]
Schedule of effective portion of risk-management instruments that was recognized in other comprehensive income (loss), net investment hedges
Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]
0.50% Notes Due 2033
0.50% Notes Due 2033 [Member]
0.50% Notes Due 2033 [Member]
Contingencies
Commitments and Contingencies Disclosure [Text Block]
Current Liabilities
Liabilities, Current [Abstract]
Contingent value right, additional price per share (up to) (in dollars per share)
Business Acquisition, Contingent Value Right, Additional Price Per Share
Business Acquisition, Contingent Value Right, Additional Price Per Share
Proceeds from issuance of long-term debt
Proceeds from Issuance of Long-Term Debt
Beginning balance (in shares)
Ending balance (in shares)
Common Stock, Shares, Issued
Summary of the fair value of available-for-sale securities in an unrealized gain or loss position
Unrealized Gain (Loss) on Investments [Table Text Block]
Retirement Plan Type [Domain]
Retirement Plan Type [Domain]
Reclassification out of Accumulated Other Comprehensive Income
Reclassification out of Accumulated Other Comprehensive Income [Member]
Acquisitions
Asset Acquisition [Text Block]
Cash Flow Hedging
Cash Flow Hedging [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of securities in an unrealized loss position
Debt Securities, Available-for-Sale, Unrealized Loss Position
Amendment Flag
Amendment Flag
Net Cash Used for Investing Activities
Net Cash Provided by (Used in) Investing Activities
Fair Value Hedging
Fair Value Hedging [Member]
Debt instrument, face amount
Debt Instrument, Face Amount
Acquired IPR&D Expense
Payments for Asset Acquisitions
Payments for Asset Acquisitions
Other comprehensive income (loss), net of tax (Note 10)
Net other comprehensive income (loss)
Other Comprehensive Income (Loss), Net of Tax
Issuance of stock under employee stock plans, net
Stock Issued During Period, Value, Employee Stock Purchase Plan
Comprehensive income
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Summary certain fair value information, liabilities
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]
Litigation Case [Axis]
Litigation Case [Axis]
Cymbalta®
Cymbalta [Member]
Cymbalta [Member]
Unrealized gross gains
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax
Entity Current Reporting Status
Entity Current Reporting Status
Other current liabilities
Other Liabilities, Current
Deferred tax liabilities
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities
Other noncurrent assets
Other Assets, Noncurrent
Milestone Payments, Capitalized as Intangible Assets
Milestone Payments, Capitalized As Intangible Assets [Member]
Milestone Payments, Capitalized As Intangible Assets
Cross-currency interest rate swaps
Cross Currency Interest Rate Contract [Member]
Depreciation and amortization
Depreciation, Depletion and Amortization
Disaggregation of Revenue [Table]
Disaggregation of Revenue [Table]
Japan
JAPAN
Issuance of stock under employee stock plans, net (in shares)
Stock Issued During Period, Shares, Employee Stock Purchase Plans
Schedule of the amounts recognized for assets acquired and liabilities assumed
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]
Accumulated Other Comprehensive Income (Loss) [Table]
Accumulated Other Comprehensive Income (Loss) [Table]
Reclassification out of Accumulated Other Comprehensive Income [Table]
Reclassification out of Accumulated Other Comprehensive Income [Table]
Entity Incorporation, State or Country Code
Entity Incorporation, State or Country Code
Other
Stockholders' Equity, Other
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Fair value of CVR liability
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability
Effect of exchange rate changes on cash and cash equivalents
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations
Property and equipment, net of accumulated depreciation of $10,074.0 (2022) and $9,976.7 (2021)
Property, Plant and Equipment, Net
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]
Repayments of long-term debt
Repayments of Long-Term Debt
Contingent value right, additional price per share, aggregate amount
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High
Other–Net, (Income) Expense
Other Income and Other Expense Disclosure [Text Block]
Cash dividends declared
Dividends
Debt Instrument, Redemption, Period [Domain]
Debt Instrument, Redemption, Period [Domain]
Allowances for doubtful accounts
Accounts Receivable, Allowance for Credit Loss, Current
Other–net, (income) expense
Other (income) expense
Other Nonoperating Income (Expense)
Long-term debt, including current portion
Long-term debt, including current portion
Long-Term Debt
1.700% Notes due 2049
1.700% Notes Due 2049 [Member]
1.700% Notes due 2049 [Member]
Acquired in-process research and development and development milestones (Note 3)
Acquired in-process research and development and development milestones
Acquired In-Process Research And Development And Development Milestones
Acquired In-Process Research And Development And Development Milestones
Statement of Comprehensive Income [Abstract]
Statement of Comprehensive Income [Abstract]
Maximum
Maximum [Member]
Accumulated other comprehensive loss (Note 10)
Accumulated Other Comprehensive Income (Loss), Net of Tax
Maturity Date 2023
Maturity Date 2023 [Member]
Maturity Date 2023 [Member]
Common Stock (no par value)
Common Class A [Member]
Schedule of Business Acquisitions, by Acquisition [Table]
Schedule of Business Acquisitions, by Acquisition [Table]
Cash and cash equivalents (Note 6)
Cash and Cash Equivalents, at Carrying Value
Available-for-sale, percentage of nonperforming assets
Debt Securities, Available-for-Sale, Unrealized Loss Position, Qualitative Disclosure, Other, Percentage of Nonperforming Assets
Debt securities, available-for-sale, unrealized loss position, qualitative disclosure, other, percentage of nonperforming assets.
Equity securities, net unrealized gains (losses)
Net investment (gains) losses on equity securities (Note 6)
Equity Securities, FV-NI, Gain (Loss)
Total current assets
Assets, Current
Designated as Hedging Instrument
Designated as Hedging Instrument [Member]
Income taxes payable
Taxes Payable, Current
Other immunology
Other Immunology [Member]
Other Immunology [Member]
Business Acquisition [Line Items]
Business Acquisition [Line Items]
Entity Small Business
Entity Small Business
Measurement Basis [Axis]
Measurement Basis [Axis]
Schedule of net pension and retiree health benefit (income) cost
Schedule of Net Benefit Costs [Table Text Block]
Cash dividend declared per share (in dollars per share)
Common Stock, Dividends, Per Share, Declared
Summary certain fair value information, assets
Fair Value, Assets Measured on Recurring Basis [Table Text Block]
1.625% Notes due 2043
1.625% Notes Due 2043 [Member]
1.625% Notes Due 2043
Derivative asset, notional amount
Derivative Asset, Notional Amount
Equity method investments
Other Long-Term Investments
COVID-19 antibodies
COVID-19 Antibodies [Member]
COVID-19 Antibodies
BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc [Member]
BioMarin Pharmaceutical Inc
Title of 12(b) Security
Title of 12(b) Security
Schedule of Defined Benefit Plans Disclosures [Table]
Schedule of Defined Benefit Plans Disclosures [Table]
Basis of Presentation and Implementation of New Financial Accounting Standard
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]
Fair value of securities in an unrealized gain position
Debt Securities, Available-for-sale, Unrealized Gain Position
Debt Securities, Available-for-sale, Unrealized Gain Position
Short-term investments (Note 6)
Short-Term Investments
Other noncurrent assets
Derivative Asset, Noncurrent
Business Combination and Asset Acquisition [Abstract]
Income Tax Contingency [Line Items]
Income Tax Contingency [Line Items]
U.S. government and agency securities
US Government Agencies Debt Securities [Member]
Foreign Currency Denominated Debt
Foreign Currency Denominated Debt [Member]
Foreign Currency Denominated Debt [Member]
Liabilities and Equity
Liabilities and Equity [Abstract]
Estimate of Fair Value Measurement
Estimate of Fair Value Measurement [Member]
0.625% Notes due 2031
.625% Notes Due 2031 [Member]
.625% Notes due 2031 [Member]
Fair Value, Recurring and Nonrecurring [Table]
Fair Value, Recurring and Nonrecurring [Table]
Emgality Patent Litigation
Emgality Patent Litigation [Member]
Emgality Patent Litigation [Member]
Change in Accounting Estimate [Line Items]
Change in Accounting Estimate [Line Items]
Shares used in calculation of earnings per share:
Weighted Average Number of Shares Outstanding, Diluted [Abstract]
Inventories
Inventory, Net
Akouos Acquisition
Akouos Acquisition [Member]
Akouos Acquisition [Member]
Accounts payable
Accounts Payable, Current
Prior service benefits, net
Accumulated Defined Benefit Plans Adjustment, Net Prior Service Including Portion Attributable to Noncontrolling Interest [Member]
Sell Euro
Sell Euro [Member]
Sell Euro [Member]
1.125% Notes due 2051
1.125% Notes Due 2051 [Member]
1.125% Notes Due 2051
1.625% Notes due 2026
1.625% Notes Due June 2, 2026 [Member]
1.625% Notes Due June 2, 2026 [Member]
Hedging Relationship [Domain]
Hedging Relationship [Domain]
Hedging Designation [Axis]
Hedging Designation [Axis]
Insulin
Insulin [Member]
Insulin
Entity Filer Category
Entity Filer Category
Eli Lilly and Company Shareholders' Equity
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Basic (in shares)
Weighted Average Number of Shares Outstanding, Basic
U.S.
UNITED STATES
Employee benefit trust
Common Stock, Shares Held in Employee Trust
Commitments and Contingencies (Note 9)
Commitments and Contingencies
Security Exchange Name
Security Exchange Name
Employee Benefit Trust
Trust for Benefit of Employees [Member]
Derivative, notional amount
Derivative, Notional Amount
Tyvyt®
TYVYT [Member]
TYVYT
Service cost
Defined Benefit Plan, Service Cost
Short-term borrowings and current maturities of long-term debt
Debt, Current
Other Liabilities
Liabilities, Noncurrent [Abstract]
Cover [Abstract]
Cover [Abstract]
Significant Unobservable Inputs (Level 3)
Fair Value, Inputs, Level 3 [Member]
Noncurrent investments
Debt Securities, Available-for-Sale, Noncurrent
Purchases of noncurrent investments
Payments to Acquire Long-Term Investments
Restructuring and Related Activities [Abstract]
Restructuring and Related Activities [Abstract]
Number of sites jointly and severally liable for cleanup (fewer than)
Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup
Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup
Change in deferred income taxes
Increase (Decrease) in Deferred Income Taxes
Revenue
Revenue from Contract with Customer [Text Block]
Cash acquired
Cash Acquired from Acquisition
Oncology
Oncology [Member]
Revenue to unaffiliated customers, Oncology
Noncontrolling Interests
Noncontrolling Interest [Member]
Other receivables
Derivative Asset, Current
Forecast
Forecast [Member]
Milestone Payments, Success-based Regulatory and Sales-based
Milestone Payments, Success-based Regulatory And Sales-based [Member]
Milestone Payments, Success-based Regulatory And Sales-based
Emgality®
Emgality [Member]
Emgality [Member]
Milestone Payments, Development and Regulatory
Milestone Payments, Development and Regulatory [Member]
Milestone Payments, Development and Regulatory [Member]
Receivables, Net, Current [Abstract]
Receivables, Net, Current [Abstract]
Total liabilities and equity
Liabilities and Equity
Cost
Portion at Other than Fair Value Measurement [Member]
Debt instrument, term
Debt Instrument, Term
Collaborative Arrangements and Non-collaborative Arrangements [Axis]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Effect from hedged fixed-rate debt
Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge
Long-term Debt, Type [Axis]
Long-Term Debt, Type [Axis]
Extinguishment of debt, amount
Extinguishment of Debt, Amount
Stock repurchase program, remaining authorized amount
Stock Repurchase Program, Remaining Authorized Repurchase Amount
6.77% Notes due 2036
6.77% Notes Due January 1, 2036 [Member]
6.77% Notes Due January 1, 2036 [Member]
Outside U.S.
Non-US [Member]
Sales rebates and discounts
Sales Rebates And Discounts
Sales Rebates And Discounts
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Not Designated as Hedging Instrument
Not Designated as Hedging Instrument [Member]
Cash paid for acquisitions, net of cash acquired (Note 3)
Cash paid, net of cash acquired
Payments to Acquire Businesses, Net of Cash Acquired
Significant Other Observable Inputs (Level 2)
Fair Value, Inputs, Level 2 [Member]
Current Fiscal Year End Date
Current Fiscal Year End Date
Total
Derivative Instruments, Gain (Loss) Recognized
Derivative Instruments, Gain (Loss) Recognized
Cialis®
Cialis [Member]
Cialis [Member]
Other intangibles, net
Intangible Assets, Net (Excluding Goodwill)
Diluted (in dollars per share)
Earnings Per Share, Diluted
Other securities, noncurrent investments
Other Equity Securities [Member]
Other Equity Securities [Member]
Total current liabilities
Liabilities, Current
More Than 10 Years
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10
Long-term income taxes payable
Accrued Income Taxes, Noncurrent
Collaboration and other revenue
Collaboration and Other Revenue [Member]
Collaboration and Other Revenue [Member]
Corporate debt securities
Corporate Debt Securities [Member]
Nonoperating Income (Expense) [Abstract]
Nonoperating Income (Expense) [Abstract]
Royalty Agreement Terms
Royalty Agreement Terms [Member]
Entity Address, Address Line One
Entity Address, Address Line One
Benefit (expense) for income taxes allocated to other comprehensive income (loss) items
Other Comprehensive Income (Loss), Tax
Other financing activities, net
Proceeds from (Payments for) Other Financing Activities
Contract liabilities
Remaining contract liabilities
Contract with Customer, Liability
Consideration transferred, number of contingent value rights
Business Combination, Consideration Transferred, Number Of Contingent Value Rights
Business Combination, Consideration Transferred, Number Of Contingent Value Rights
Intangible asset impairment
Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)
Product and Service [Axis]
Product and Service [Axis]
1.375% Notes due 2061
1.375% Notes Due 2061 [Member]
1.375% Notes Due 2061
Europe
Europe [Member]
Class of Stock [Domain]
Class of Stock [Domain]
Expected return on plan assets
Defined Benefit Plan, Expected Return (Loss) on Plan Assets
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Abstract]
Interest expense
Interest Expense
3.375% Notes Due 2029
3.375% Notes Due 2029 [Member]
3.375% Notes Due 2029 [Member]
Retirement Plan Type [Axis]
Retirement Plan Type [Axis]
Prevail Therapeutics Inc.
Prevail Therapeutics Inc. [Member]
Prevail Therapeutics Inc.
Humulin®
Humulin [Member]
Humulin [Member]
Equity [Abstract]
Equity [Abstract]
Humalog®
Humalog [Member]
Humalog [Member]
Jardiance
Jardiance [Member]
Jardiance [Member]
Other receivables
Other Receivables, Net, Current
Entity Tax Identification Number
Entity Tax Identification Number
Unfavorable Regulatory Action
Unfavorable Regulatory Action [Member]
Maximum remaining maturity of foreign currency derivatives
Maximum Remaining Maturity of Foreign Currency Derivatives
Forteo®
Forteo [Member]
Forteo [Member]
Schedule of disaggregation of revenue
Disaggregation of Revenue [Table Text Block]
Revenue from Contract with Customer [Abstract]
Revenue from Contract with Customer [Abstract]
Trajenta
Trajenta (BI) [Member]
Trajenta (BI) [Member]
Dividends payable
Dividends Payable, Current
Net decrease in cash and cash equivalents
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect
Roche
Roche [Member]
Roche [Member]
Schedule of components of the charges included in asset impairment, restructuring, and other special charges
Restructuring and Related Costs [Table Text Block]
Entity Central Index Key
Entity Central Index Key
Interest income
Investment Income, Interest
Research and Development Expenses and Acquired In-Process Research and Development (IPR&D) and Developmental Milestones
Research and Development Expense, Policy [Policy Text Block]
Buy U.S. Dollars Sell Japanese Yen
Buy US dollar Sell Japanese Yen [Member]
Buy US dollar Sell Japanese Yen [Member]
Buy Euros Sell U.S. Dollars
Buy Euro Sell Us Dollar [Member]
Foreign Currency Forward Commitment to Buy euro Sell US dollar
Collaborations and Other Arrangements
Collaborative Arrangement Disclosure [Text Block]
Buy U.S. Dollars Sell Euros
Buy Us Dollar Sell Euro [Member]
Foreign Currency Forward commitment to Buy US dollar Sell euro
Loss Contingency Nature [Axis]
Loss Contingency Nature [Axis]
Entity [Domain]
Entity [Domain]
City Area Code
City Area Code
Assets
Assets [Abstract]
Other changes in operating assets and liabilities, net of acquisitions and divestitures
Increase (Decrease) in Other Operating Assets and Liabilities, Net
Retirement Benefits [Abstract]
Retirement Benefits [Abstract]
Long-term Debt, Type [Domain]
Long-Term Debt, Type [Domain]
Other securities
Other Debt Obligations [Member]
Swap U.S. Dollars to Euro
Swap U.S. Dollars To Euro [Member]
Swap U.S. Dollars To Euro [Member]
Statement of Stockholders' Equity [Abstract]
Statement of Stockholders' Equity [Abstract]
Alternative investments, unfunded commitments
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Unfunded Commitments
Debt Instrument, Redemption, Period [Axis]
Debt Instrument, Redemption, Period [Axis]
Cash Flows from Financing Activities
Net Cash Provided by (Used in) Financing Activities [Abstract]
Schedule of activity related to our available-for-sale securities
Gain (Loss) on Securities [Table Text Block]
Mortgage-backed securities
Collateralized Mortgage-Backed Securities [Member]
Stock-based compensation expense
Share-Based Payment Arrangement, Noncash Expense
Other noncurrent liabilities
Other Liabilities, Noncurrent
Interest Rate Contracts
Interest Rate Contract [Member]
Retirement of treasury shares
Treasury Stock, Retired, Cost Method, Amount
Mounjaro®
Mounjaro [Member]
Mounjaro [Member]
Disaggregation of Revenue [Line Items]
Disaggregation of Revenue [Line Items]
Percentage of long-term fixed-rate notes to floating rates through the use of interest rate swaps converted
Description of Derivative Activity Volume Percent
Description of Derivative Activity Volume Percent
Zyprexa®
Zyprexa [Member]
Zyprexa [Member]
Retiree Health Benefit Plans
Other Postretirement Benefits Plan [Member]
Other noncurrent liabilities
Derivative Liability, Noncurrent